BioLineRx Annouces Expansion of 2016 Collaboration with Merck&Co. in Immuno-Oncology in pancreatic cancer
BioLineRx Annouces Expansion of 2016 Collaboration with Merck&Co. in Immuno-Oncology in pancreatic cancer
Shots:
- Under the expansion collaboration, new arm of assessment is added assessing BL-8040, Keytruda and chemo in 2L patient in COMBAT/KEYNOTE-202 study
- Results of Ph2a COMBAT study is expected in H2’18 as planned
- This study is assessing combination of BL-8040 & Keytruda in metastatic 1L+ patients